Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.
Antoine HollebecqueStefania SalvagniRuth PlummerNicolas IsambertPatricia NiccoliJaume CapdevilaGiuseppe CuriglianoVictor MorenoPatricia Martin-RomanoEric BaudinMarina AriasSheila MoraJuan de AlvaroJorge Di MartinoJosep L Parra-PalauTania Sánchez-PérezIda AronchikEllen H FilvaroffManisha LambaZariana NikolovaJohann S de BonoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
CC-90011 is well tolerated, with the RP2D established as 60 mg once per week. The MTD and NTD were determined to be 80 mg once per week and 120 mg once per week, respectively. Further evaluation of CC-90011 is warranted.